Van Eck Associates Corp Ionis Pharmaceuticals Inc Transaction History

Van Eck Associates Corp

$77.4 Billion
Q1 2025

A detailed history of Van Eck Associates Corp transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Van Eck Associates Corp holds 2,157 shares of IONS stock, worth $88,803. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,157

Previous 61,619 96.5%

Holding current value

$88,803

Previous $2.15 Million 96.98%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$30.17 - $34.97 $1.79 Million - $2.08 Million	-59,462 Reduced 96.5%	2,157 $65,000
Q4 2024 Jan 29, 2025	BUY	$33.73 - $40.36 $88,136 - $105,460	2,613 Added 4.43%	61,619 $2.15 Million
Q3 2024 Oct 29, 2024	BUY	$40.06 - $51.86 $350,204 - $453,360	8,742 Added 17.39%	59,006 $2.27 Million
Q2 2024 Jul 31, 2024	SELL	$36.45 - $47.7 $1.49 Million - $1.95 Million	-40,837 Reduced 44.83%	50,264 $2.4 Million
Q1 2024 Apr 30, 2024	BUY	$42.03 - $53.55 $1.06 Million - $1.35 Million	25,270 Added 38.39%	91,101 $3.95 Million
Q4 2023 Feb 05, 2024	BUY	$43.39 - $51.63 $49,638 - $59,064	1,144 Added 1.77%	65,831 $3.33 Million
Q3 2023 Nov 08, 2023	BUY	$38.5 - $47.13 $1.28 Million - $1.57 Million	33,326 Added 106.27%	64,687 $2.93 Million
Q2 2023 Aug 03, 2023	BUY	$34.73 - $43.33 $423,219 - $528,019	12,186 Added 63.55%	31,361 $1.29 Million
Q1 2023 May 03, 2023	BUY	$33.58 - $41.2 $239,526 - $293,879	7,133 Added 59.23%	19,175 $685,000
Q4 2022 Feb 08, 2023	BUY	$37.12 - $46.52 $394,400 - $494,275	10,625 Added 749.82%	12,042 $455,000
Q3 2022 Oct 27, 2022	BUY	$36.54 - $48.66 $51,777 - $68,951	1,417 New	1,417 $63,000
Q3 2021 Nov 03, 2021	SELL	$33.54 - $40.55 $4.94 Million - $5.98 Million	-147,383 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$34.54 - $47.25 $780,914 - $1.07 Million	-22,609 Reduced 13.3%	147,383 $5.88 Million
Q1 2021 May 13, 2021	BUY	$42.51 - $63.78 $1.84 Million - $2.76 Million	43,349 Added 34.23%	169,992 $7.64 Million
Q4 2020 Feb 09, 2021	BUY	$45.3 - $60.27 $32,842 - $43,695	725 Added 0.58%	126,643 $7.16 Million
Q3 2020 Nov 12, 2020	SELL	$47.45 - $62.95 $807,171 - $1.07 Million	-17,011 Reduced 11.9%	125,918 $5.98 Million
Q2 2020 Aug 10, 2020	BUY	$46.85 - $61.05 $2.87 Million - $3.73 Million	61,163 Added 74.8%	142,929 $8.43 Million
Q1 2020 May 12, 2020	SELL	$41.6 - $63.4 $923,312 - $1.41 Million	-22,195 Reduced 21.35%	81,766 $3.87 Million
Q4 2019 Feb 13, 2020	SELL	$53.85 - $65.27 $67,689 - $82,044	-1,257 Reduced 1.19%	103,961 $6.28 Million
Q3 2019 Nov 08, 2019	BUY	$59.06 - $72.15 $78,904 - $96,392	1,336 Added 1.29%	105,218 $6.3 Million
Q2 2019 Aug 07, 2019	SELL	$62.09 - $86.14 $1.15 Million - $1.59 Million	-18,491 Reduced 15.11%	103,882 $6.68 Million
Q1 2019 May 13, 2019	SELL	$52.92 - $81.17 $555,818 - $852,528	-10,503 Reduced 7.9%	122,373 $9.93 Million
Q4 2018 Feb 12, 2019	SELL	$43.37 - $59.54 $199,285 - $273,586	-4,595 Reduced 3.34%	132,876 $7.18 Million
Q3 2018 Nov 13, 2018	BUY	$42.88 - $53.7 $33,232 - $41,617	775 Added 0.57%	137,471 $7.09 Million
Q2 2018 Aug 13, 2018	BUY	$40.53 - $50.7 $871,800 - $1.09 Million	21,510 Added 18.67%	136,696 $5.7 Million
Q1 2018 May 11, 2018	SELL	$44.08 - $55.05 $2.39 Million - $2.98 Million	-54,161 Reduced 31.98%	115,186 $5.08 Million
Q4 2017 Feb 12, 2018	SELL	$50.3 - $64.39 $4.44 Million - $5.69 Million	-88,358 Reduced 34.29%	169,347 $8.52 Million
Q3 2017 Nov 09, 2017	BUY	$45.56 - $59.57 $844,910 - $1.1 Million	18,545 Added 7.75%	257,705 $13.1 Million
Q2 2017 Aug 11, 2017	BUY	N/A	239,160	239,160 $12.2 Million

Others Institutions Holding IONS

# of Institutions

400

Shares Held

145M

Call Options Held

916K

Put Options Held

541K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.84B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Eck Associates Corp, based on Form 13F filings with the SEC.

News

Stay updated on Van Eck Associates Corp with notifications on news.

Account

Van Eck Associates Corp Ionis Pharmaceuticals Inc Transaction History